schisandrin/stroke

鏈接已保存到剪貼板

文章臨床試驗專利權

選擇排序類型

3 結果

Schisandrin B improves cerebral ischemia and reduces reperfusion injury in rats through TLR4/NF-κB signaling pathway inhibition

只有註冊用戶可以翻譯文章

登陸註冊

It has been established that poor outcomes in ischemic stroke patients are associated with the post-reperfusion inflammatory response and up-regulation of TLR4. Therefore, suppression of the TLR4 signaling pathway constitutes a potential neuroprotective therapeutic strategy. Schisandrin B, a

Qualitative and quantitative analysis of multiple components for quality control of Deng-Zhan-Sheng-Mai capsules by ultra high performance liquid chromatography tandem mass spectrometry method coupled with chemometrics.

只有註冊用戶可以翻譯文章

登陸註冊

Deng-Zhan-Sheng-Mai capsules are a well-known traditional Chinese patent medicine that was developed in China for the treatment of ischemic stroke. Its quality control focuses on Erigerontis Herba but ignores the contributions of Ginseng Radix et Rhizoma, Schisandrae Chinensis Fructus, and

The Traditional Chinese Medicine Compound, GRS, Alleviates Blood-Brain Barrier Dysfunction.

只有註冊用戶可以翻譯文章

登陸註冊

Traditional Chinese medicine (TCM) provides unique advantages for treatment of ischemic stroke, an aging-related vascular disease. Shengmai powder (GRS) is composed of three active components, specifically, ginsenoside Rb1, ruscogenin and schisandrin A, at a ratio of 6:0.75:6. The main

加入我們的臉書專頁

Herbal & Natural Medicine

科學支持的最完整的草藥數據庫

支持55種語言
科學支持的草藥療法
通過圖像識別草藥
交互式GPS地圖-在位置標記草藥（即將推出）
閱讀與您的搜索相關的科學出版物
通過藥效搜索藥草
組織您的興趣並及時了解新聞研究，臨床試驗和專利

輸入症狀或疾病，並閱讀可能有用的草藥，輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究